Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

S. Massironi, D. Campana, S. Pusceddu, M. Albertelli, A. Faggiano, F. Panzuto, V. Smiroldo, V. Andreasi, R.E. Rossi, I. Maggio, M. Torchio, A. Dotto, R. Modica, M. Rinzivillo, C. Carnaghi, S. Partelli, I. Fanetti, G. Lamberti, F. Corti, D. FeroneA. Colao, B. Annibale, P. Invernizzi, M. Falconi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Patients with sporadic neuroendocrine neoplasms may exhibit a higher risk of a second primary tumor than the general population. Aim: This study aimed to analyze the occurrence of second primary malignancies. Methods: A retrospective cohort of 2757 patients with sporadic lung and gastro-entero-pancreatic neuroendocrine neoplasms, managed at eight Italian tertiary referral Centers, was included. Results: Between 2000 and 2019, a second primary malignancy was observed in 271 (9.8%) neuroendocrine neoplasms patients with 32 developing a third tumor. There were 135 (49.8%) females and the median age was 64 years. The most frequent locations of the second tumors were breast (18.8%), prostate (12.5%), colon (9.6%), blood tumors (8.5%), and lung (7.7%). The second primary tumor was synchronous in 19.2% of cases, metachronous in 43.2%, and previous in 37.6%. As concerned the neuroendocrine neoplasms, the 5- and 10-year survival rates were 87.8% and 74.4%, respectively. PFS for patients with a second primary malignancy was shorter than for patients without a second primary malignancy. Death was mainly related to neuroendocrine neoplasms. Conclusion: In NEN patients the prevalence of second primary malignancies was not negligible, suggesting a possible neoplastic susceptibility. Overall survival was not affected by the occurrence of a second primary malignancy.

Original languageEnglish
JournalDigestive and Liver Disease
DOIs
Publication statusPublished - 2020

Cite this